Balyasny Asset Management’s CureVac CVAC Stock Holding History

Balyasny Asset Management’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-343,500	Closed	-$6.74M	–	2825
2022 Q1	$6.74M	Buy	+343,500	New	+$6.86M	0.02%	838

Other funds holding CVAC

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Balyasny Asset Management's CVAC Position: Q1 2024 in Review

Balyasny Asset Management sold out of CureVac (CVAC) in Q1 2024, closing a stake of 26,317 shares — an estimated $111K sold.

Balyasny Asset Management first reported a position in CVAC in Q1 2022 and held it in 6 quarters. The position peaked at $8.44M in Q4 2022. 90 funds tracked by Wall St. Rank hold CVAC as of Q1 2024.

Balyasny Asset Management reported no remaining CureVac position as of Q1 2024 after selling out during the quarter.
Balyasny Asset Management sold 26,317 CureVac shares in Q1 2024, an estimated $111K.
Balyasny Asset Management first reported a position in CureVac in Q1 2022 and held it in 6 quarters.
Balyasny Asset Management's CureVac position peaked at $8.44M in Q4 2022.
90 funds tracked by Wall St. Rank held CureVac as of Q1 2024.

Based on Balyasny Asset Management's 13F filing for Q1 2024, filed 13 May 2024.